Form 4: Elanco Animal Health CEO Jeffrey Simmons Reports Acquisition of Deferred Stock Units

Sentiment:

SEC Form 4 Filing


Elanco Animal Health's CEO, Jeffrey Simmons, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

Summary

  • Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., filed a Form 4 with the SEC.
  • The filing reports the acquisition of deferred stock units on June 28, 2024.
  • These deferred stock units can be converted into shares of Elanco common stock or their cash equivalent.
  • Mr. Simmons acquired 191.9085 deferred stock units at a price of $14.43, resulting in 2,306.184 derivative securities beneficially owned.
  • The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard executive compensation practice. The acquisition of deferred stock units is neither overtly positive nor negative.

Positives

  • The acquisition of deferred stock units by the CEO demonstrates confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

Executive compensation through stock and deferred stock units is a common practice in the animal health industry to align management's interests with those of shareholders.

Comparison to Industry Standards

  • Companies like Zoetis and Merck Animal Health also utilize stock-based compensation for their executives.
  • The specific terms of deferred stock unit plans vary, but the general structure is consistent with industry norms for incentivizing long-term performance.

Stakeholder Impact

  • The acquisition of deferred stock units aligns the CEO's interests with those of shareholders, potentially driving long-term value creation.

Key Dates

DateDescription
06/28/2024Date of the transaction involving the acquisition of deferred stock units.
07/02/2024Date of the signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.